Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | TACR2 | P21452 | 16/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5600846 | 0.85 | CHRNA7 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5600774 | 0.83 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1837268 | 0.82 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10052926 | 0.76 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1839461 | 0.73 | CTSL (0.48) | — | |
| SCHEMBL121300 | 0.73 | HDAC1 (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31207866 | 0.69 | HDAC1 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2250510 | 0.69 | HDAC1 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3304077 | 0.69 | HDAC1 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3428350 | 0.69 | CTSL (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102428081-B | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI SAS | 2014-09-17 | — | — | CN | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| EP-2432778-B1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI SAS (IT) | 2013-03-20 | — | — | EP | disclosed |
| EP-2432778-B1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI SAS (IT) | 2013-03-20 | — | — | EP | disclosed |
| CN-102428081-A | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI SAS | 2012-04-25 | — | — | CN | disclosed |
| EP-2432778-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | Malesci Istituto Farmacobiologico S.p.a. (IT) | 2012-03-28 | — | — | EP | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | DDT, BBOX1, IMPDH2 | HDAC3 4688/4885HDAC4 4854/4885HDAC1 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.